MYOV
Myovant Sciences Ltd. [MYOV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MYOV Stock Summary
In the News
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates
Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Sumitomo Pharma Is Buying Myovant Sciences (MYOV) For $2.9 Billion
Sumitovant Biopharma recently announced it is buying Myovant Sciences (MYOV) in a $2.9 billion deal. This is why.
Myovant Sciences Cancels Second Quarter Earnings Conference Call
BASEL, Switzerland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“Myovant”) today announced the cancellation of its earnings conference call for the quarter ended September 30, 2022 that had originally been scheduled for October 26, 2022 at 5:00 p.m. Eastern Time. The call is being cancelled due to the announcement of the pending merger with Sumitovant Biopharma Ltd.
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant Sciences
Today's market-moving news in the drugmaker sector is that Sumitomo Pharma and a subsidiary have agreed to buy out the remainder of Myovant Sciences (NYSE: MYOV ) that they don't already own. Furthermore, they raised their offer to make this purchase.
Why Myovant Sciences Stock Is Moving Higher - Myovant Sciences (NYSE:MYOV)
Myovant Sciences Ltd (NYSE: MYOV) shares are trading higher Monday after the company announced it will be acquired by Sumitovant Biopharma for $27 per share in cash.
Myovant Sciences shares trading higher after agreeing to Sumitomo deal for $2.9 billion
Shares of Myovant Sciences Ltd. MYOV, +0.95% were up 8.2% in premarket trading on Monday, the day after the company said it will be acquired by Sumitomo Pharma Co. Ltd.
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022. The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on October 26, 2022.
Myovant Sciences: What The Sumitomo Offer Foretells
As Myovant overcame the odds as I forecast, Myfembree garnered another FDA approval to treat endometriosis. Subsequent to the said game-changing event, Sumitomo made an offer to acquire all outstanding shares at $22.75. However, Myovant's Board rejected the offer.
Myovant: Sumitomo Bid Is A Head Scratcher, Where Is The Value?
Myovant stock has rocketed in value by >100% since my last (bearish) note on the company. The main reason for the Myovant gains is an attempt by majority shareholder Sumitomo to acquire remaining shares for $22.75 per share.
MYOV Financial details
MYOV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
| Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0.66 | 2.48 | |
| Net income per share | -2.41 | -4.09 | -3.37 | -2.83 | -2.22 | |
| Operating cash flow per share | -1.97 | -3.35 | -2.58 | 4.12 | -2.89 | |
| Free cash flow per share | -1.98 | -3.37 | -2.59 | 4.1 | -2.9 | |
| Cash per share | 1.82 | 2.33 | 0.93 | 7.61 | 4.67 | |
| Book value per share | 0.63 | 0.06 | -1.26 | -3.93 | -5.09 | |
| Tangible book value per share | 0.63 | 0.06 | -1.26 | -3.93 | -5.09 | |
| Share holders equity per share | 0.63 | 0.06 | -1.26 | -3.93 | -5.09 | |
| Interest debt per share | 0.77 | 1.62 | 1.62 | 4.22 | 4.11 | |
| Market cap | 1.27B | 1.59B | 648.09M | 1.85B | 1.24B | |
| Enterprise value | 1.2B | 1.53B | 697.65M | 1.55B | 1.2B | |
| P/E ratio | -8.84 | -5.81 | -2.24 | -7.26 | -6.01 | |
| Price to sales ratio | 0 | 0 | 0 | 31.24 | 5.36 | |
| POCF ratio | -10.8 | -7.1 | -2.93 | 5 | -4.61 | |
| PFCF ratio | -10.74 | -7.06 | -2.92 | 5.02 | -4.59 | |
| P/B Ratio | 33.56 | 366.97 | -5.99 | -5.23 | -2.62 | |
| PTB ratio | 33.56 | 366.97 | -5.99 | -5.23 | -2.62 | |
| EV to sales | 0 | 0 | 0 | 26.1 | 5.19 | |
| Enterprise value over EBITDA | -8.53 | -5.81 | -2.59 | -6 | -6.52 | |
| EV to operating cash flow | -10.24 | -6.84 | -3.15 | 4.18 | -4.47 | |
| EV to free cash flow | -10.19 | -6.81 | -3.14 | 4.2 | -4.45 | |
| Earnings yield | -0.11 | -0.17 | -0.45 | -0.14 | -0.17 | |
| Free cash flow yield | -0.09 | -0.14 | -0.34 | 0.2 | -0.22 | |
| Debt to equity | 1.16 | 22.93 | -1.17 | -1.04 | -0.78 | |
| Debt to assets | 0.37 | 0.57 | 1.19 | 0.51 | 0.71 | |
| Net debt to EBITDA | 0.46 | 0.21 | -0.18 | 1.18 | 0.21 | |
| Current ratio | 3.09 | 2.32 | 1.02 | 2.5 | 1.95 | |
| Interest coverage | -68.95 | -30.02 | -21.38 | -25.07 | -13.41 | |
| Income quality | 0.82 | 0.82 | 0.77 | -1.45 | 1.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 2.3 | 0.47 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | -0.03 | 0 | |
| Capex to depreciation | -2.49 | -2.82 | -0.62 | -0.72 | -0.32 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0.9 | 0.17 | |
| Graham number | 5.86 | 2.44 | 9.77 | 15.83 | 15.93 | |
| ROIC | -1.74 | -2.56 | -8.91 | -9.77 | 1.99 | |
| Return on tangible assets | -1.2 | -1.58 | -2.73 | -0.35 | -0.4 | |
| Graham Net | 0.47 | -0.18 | -1.57 | -4.33 | -5.78 | |
| Working capital | 77.68M | 94.82M | 1.99M | 423.31M | 237.82M | |
| Tangible asset value | 37.73M | 4.33M | -108.28M | -353.97M | -473.48M | |
| Net current asset value | 33.39M | -1.85M | -126.29M | -374.35M | -505.34M | |
| Invested capital | 1.16 | 22.93 | -1.17 | -1.04 | -0.78 | |
| Average receivables | 500K | 762K | 262K | 1.79M | 13.72M | |
| Average payables | 3.95M | 7.8M | 13.18M | 16.57M | 15.03M | |
| Average inventory | 0 | 0 | 0 | 1.31M | 5.1M | |
| Days sales outstanding | 0 | 0 | 0 | 21.97 | 37.73 | |
| Days payables outstanding | 0 | 0 | 0 | 3.31K | 86.73 | |
| Days of inventory on hand | 0 | 0 | 0 | 484.99 | 53.7 | |
| Receivables turnover | 0 | 0 | 0 | 16.62 | 9.67 | |
| Payables turnover | 0 | 0 | 0 | 0.11 | 4.21 | |
| Inventory turnover | 0 | 0 | 0 | 0.75 | 6.8 | |
| ROE | -3.8 | -63.12 | 2.67 | 0.72 | 0.44 | |
| Capex per share | -0.01 | -0.02 | -0.01 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
| Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.58 | 0.61 | 1.22 | 1.09 | 1.03 | |
| Net income per share | -0.68 | -0.63 | -0.22 | -0.47 | -0.59 | |
| Operating cash flow per share | -0.98 | -1.06 | -0.8 | 0.09 | -1.06 | |
| Free cash flow per share | -0.99 | -1.06 | -0.8 | 0.09 | -1.06 | |
| Cash per share | 5.65 | 4.6 | 3.74 | 3.86 | 2.83 | |
| Book value per share | -4.62 | -5.02 | -5.07 | -5.33 | -5.76 | |
| Tangible book value per share | -4.62 | -5.02 | -5.07 | -5.33 | -5.76 | |
| Share holders equity per share | -4.62 | -5.02 | -5.07 | -5.33 | -5.76 | |
| Interest debt per share | 3.98 | 3.93 | 3.9 | 3.86 | 3.85 | |
| Market cap | 1.46B | 1.26B | 1.19B | 1.73B | 2.61B | |
| Enterprise value | 1.37B | 1.22B | 1.23B | 1.75B | 2.73B | |
| P/E ratio | -5.73 | -5.3 | -13.96 | -9.47 | -11.33 | |
| Price to sales ratio | 26.73 | 21.84 | 10.18 | 16.48 | 26.05 | |
| POCF ratio | -15.84 | -12.56 | -15.6 | 189.47 | -25.38 | |
| PFCF ratio | -15.78 | -12.53 | -15.59 | 196.22 | -25.32 | |
| P/B Ratio | -3.37 | -2.66 | -2.45 | -3.37 | -4.68 | |
| PTB ratio | -3.37 | -2.66 | -2.45 | -3.37 | -4.68 | |
| EV to sales | 25.09 | 21.17 | 10.54 | 16.72 | 27.21 | |
| Enterprise value over EBITDA | -23.19 | -23.87 | -151.92 | -54.98 | -55.19 | |
| EV to operating cash flow | -14.87 | -12.18 | -16.15 | 192.2 | -26.51 | |
| EV to free cash flow | -14.81 | -12.14 | -16.14 | 199.05 | -26.45 | |
| Earnings yield | -0.04 | -0.05 | -0.02 | -0.03 | -0.02 | |
| Free cash flow yield | -0.06 | -0.08 | -0.06 | 0.01 | -0.04 | |
| Debt to equity | -0.85 | -0.78 | -0.76 | -0.71 | -0.66 | |
| Debt to assets | 0.61 | 0.71 | 0.8 | 0.76 | 0.91 | |
| Net debt to EBITDA | 1.52 | 0.76 | -5.18 | -0.78 | -2.35 | |
| Current ratio | 2.14 | 1.95 | 1.89 | 1.83 | 1.57 | |
| Interest coverage | -17.15 | -14.87 | -2.23 | -7 | -8.48 | |
| Income quality | 1.45 | 1.69 | 3.58 | -0.2 | 1.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.47 | 0.43 | 0.21 | 0.26 | 0.31 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | -0.03 | 0 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.47 | -0.33 | -0.09 | -0.39 | -0.26 | |
| Stock based compensation to revenue | 0.13 | 0.15 | 0.08 | 0.11 | 0.11 | |
| Graham number | 8.4 | 8.42 | 5.04 | 7.54 | 8.78 | |
| ROIC | 1.11 | 0.58 | 0.14 | 0.3 | 0.29 | |
| Return on tangible assets | -0.1 | -0.11 | -0.05 | -0.09 | -0.14 | |
| Graham Net | -5.25 | -5.7 | -5.8 | -6.12 | -6.6 | |
| Working capital | 305.72M | 237.82M | 200.59M | 209.22M | 140.83M | |
| Tangible asset value | -432.28M | -473.48M | -483.52M | -513.25M | -558.14M | |
| Net current asset value | -461.82M | -505.34M | -516.83M | -536.31M | -575.08M | |
| Invested capital | -0.85 | -0.78 | -0.76 | -0.71 | -0.66 | |
| Average receivables | 16.93M | 21.67M | 26.99M | 32.41M | 39.36M | |
| Average payables | 10.39M | 12.19M | 10.9M | 8.88M | 10.22M | |
| Average inventory | 6.44M | 7.16M | 14.4M | 22.13M | 26.57M | |
| Days sales outstanding | 32.17 | 37.33 | 23.26 | 29.8 | 39.53 | |
| Days payables outstanding | 66.86 | 62.14 | 37.49 | 27.02 | 32.13 | |
| Days of inventory on hand | 37.13 | 38.47 | 83.29 | 75.81 | 79.11 | |
| Receivables turnover | 2.8 | 2.41 | 3.87 | 3.02 | 2.28 | |
| Payables turnover | 1.35 | 1.45 | 2.4 | 3.33 | 2.8 | |
| Inventory turnover | 2.42 | 2.34 | 1.08 | 1.19 | 1.14 | |
| ROE | 0.15 | 0.13 | 0.04 | 0.09 | 0.1 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
MYOV Frequently Asked Questions
What is Myovant Sciences Ltd. stock symbol ?
Myovant Sciences Ltd. is a GB stock and trading under the symbol MYOV
What is Myovant Sciences Ltd. stock quote today ?
Myovant Sciences Ltd. stock price is $26.98 today.
Is Myovant Sciences Ltd. stock public?
Yes, Myovant Sciences Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.09M
- Market Capitalization 2.62B
- Employee 579
- CEO Mr. David C. Marek
- Headquarters London,GB
- IPO Date 2016-10-27
-
Website
https://myovant.com 
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
